

Around the world session: access to therapy

**Hepatitis C: access to therapy in Morocco** 

M Benazzouz Rabat Morocco

## **Current situation of hepatitis C in Morocco**

- ✓ Prevalence: 1.2 %
- ✓ Total number of patients : 450 000
- ✓ Mortality: data not avalaible.
- ✓ Number of liver transplantations : early stage program
- ✓ Total number of patients treated so far : around 50 000
- ✓ Total number of patients treated in 2016: 6000 using DAA

## Ressources currently available

- ✓ Current ressources provided by Health Authorities (amount in euros): 3 264 150 Euros / year
- ✓ Drugs available : SOFO / DACLA / RIBA / SOFO+LEDI/ Peg
- ✓ Plans for screening : high risk population
- ✓ Plans for access to treatment :
  - Development and validation of a national plan of action
  - National guidelines for HCV management available (SMMAD)
  - Local Generic production with reduced cost
  - Involvement of patients associations

## **Actions planned**

- ✓ **To improve screening**: Raise awareness of population about the burden of HCV (TV,Media,patients associations.....). Extend screenig to all adult even without risk factors
  - To facilitate access to treatment: More cheaper generics /Access program /gouvernement involvement
- ✓ Future drugs available: Therse is a need for drugs in CKD patients.
- ✓ Major future actions planned against hepatitis C :
  - data collection
  - Promote preventive actions
  - Screening ++++
  - Reduce the number and cost of diagnostic tools ( PCR ,...)
  - Increase treatment to 20,300 per year by 2025 with high cure rate therapies
  - Treat all positive HCV patients
  - Improuve Link to care +++++
  - Increase ressources provided by Health Authorities

**Results expected:** 

>90% reduction in total infection, >65% reduction in liver related deaths and cirrhosis and >75% reduction in HCC by 2030

Source: CDA Modeling